PHASE II STUDY OF XRT + LOW-DOSE TEMOZOLOMIDE FOLLOWED BY TEMOZOLOMIDE + CPT-11

XRT 低剂量替莫唑胺随后是替莫唑胺 CPT-11 的 II 期研究

• 批准号: 7607532
• 负责人: MINESH P. MEHTA
• 金额: $ 0.09万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607532
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Dose; Drug usage; Funding; Glioblastoma; Grant; Institution; Irinotecan/Temozolomide; Newly Diagnosed; Patients; Phase; Phase II Clinical Trials; Radiation therapy; Research; Research Personnel; Resources; Source; United States National Institutes of Health; Work; chemotherapy; killings; neoplastic cell; temozolomide

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is closed to accrual. (from www.cancer.gov website) Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as temozolomide and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. This Phase II trial is studying how well radiation therapy, temozolomide, and irinotecan work in reating patients with newly diagnosed glioblastoma multiforme.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 这项研究已停止计提。 （来自 www.cancer.gov 网站） 放射治疗使用高能 X 射线来破坏肿瘤细胞。化疗中使用的药物，如替莫唑胺和伊立替康，以不同的方式发挥作用，阻止肿瘤细胞分裂，使其停止生长或死亡。放射治疗与化疗相结合可能会杀死更多的肿瘤细胞。 这项 II 期试验正在研究放射疗法、替莫唑胺和伊立替康对新诊断的多形性胶质母细胞瘤患者的治疗效果。